The FDA should restrict barzolvolimab to a last-line therapy for chronic hives

From the articleCelldex shares slip 15% as safety concerns cloud skin drug trial winAlso in Celldex sinks as safety concerns cloud immune drug results, Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints